# TRIBE2 (NCT02339116)

> Folfoxiri Plus Bev Followed by Reintroduction of Folfoxiri Plus Bev at Progression Versus Folfox Plus Bev Followed by Folfiri Plus Bev in mCRC

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02339116
- Phase: PHASE3
- Status: UNKNOWN
- Sponsor: Gruppo Oncologico del Nord-Ovest
- Conditions: Metastatic Colorectal Cancer
- Interventions: fluoruracil; Oxaliplatin; Irinotecan; Bevacizumab
- Enrollment: 654
- Primary outcome: Progression Free Survival 2 (PFS2)

## Commentary we found

- X threads: 16
- Podcasts: 4
- YouTube: 3

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=tribe2-nct02339116

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02339116", "email": "<work email>"}; the inbox owner confirms by the emailed link.